ArticleEndocrine-related cancer2026
Long-term calcitonin after thyroidectomy for medullary thyroid cancer in MEN2A.
Article in Endocrine-related cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thyroidectomy is recommended for patients with multiple endocrine neoplasia type 2A (MEN2A). American Thyroid Association 2015 guidelines recommend follow-up of calcitonin values after thyroidectomy. The aim of this study was to determine the natural course of calcitonin levels after total thyroidectomy (TTx) in MEN2A patients. Patients with MEN2A who underwent TTx between 1993 and 2019 and had multiple postoperative calcitonin measurements were retrospectively included from our referral center. Long-term serial calcitonin measurements and clinical outcomes were correlated to the first postoperative calcitonin, histopathology and type of TTx (prophylactic versus non-prophylactic). Fifty-two patients underwent TTx after 1993 at a median age of 10 years (range 0-71). Of these, 23 (44%) had no MTC and 29 (56%) had MTC. The median follow-up time was 12 years (range 3-30). Thirty-eight patients had an 'undetectable' first postoperative calcitonin, seven 'within reference range' and seven 'above reference range'. Of the 38 patients with an 'undetectable' first postoperative calcitonin, 32 remained 'undetectable'. All 21 patients without MTC and 'undetectable' first postoperative calcitonin remained 'undetectable'. Of the 17 patients with MTC and 'undetectable' first postoperative calcitonin, 11 remained 'undetectable' and none developed structural recurrence. Twenty-two of the 25 patients undergoing prophylactic thyroidectomy had repeated 'undetectable' measurements. Persistent MTC or structural recurrence occurred in six patients; all had MTC, had a detectable first postoperative calcitonin and underwent non-prophylactic TTx. In conclusion, the long-term serial calcitonin values remain undetectable in the majority of the patients with an undetectable first postoperative calcitonin. Biochemical follow-up for patients without MTC and an undetectable first postoperative calcitonin may not be necessary.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.